ZIVO Bioscience (ZIVO) Competitors $18.00 0.00 (0.00%) As of 05/23/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock ZIVO vs. RNAC, TSVT, ALMS, INZY, GLUE, TERN, PVLA, LFCR, TNGX, and GOSSShould you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Alumis (ALMS), Inozyme Pharma (INZY), Monte Rosa Therapeutics (GLUE), Terns Pharmaceuticals (TERN), Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR), Tango Therapeutics (TNGX), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. ZIVO Bioscience vs. Cartesian Therapeutics 2seventy bio Alumis Inozyme Pharma Monte Rosa Therapeutics Terns Pharmaceuticals Palvella Therapeutics Lifecore Biomedical Tango Therapeutics Gossamer Bio Cartesian Therapeutics (NASDAQ:RNAC) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership, community ranking and media sentiment. Do insiders & institutionals believe in RNAC or ZIVO? 86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 57.9% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer RNAC or ZIVO? ZIVO Bioscience received 60 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 60.74% of users gave ZIVO Bioscience an outperform vote. CompanyUnderperformOutperformCartesian TherapeuticsOutperform Votes3995.12% Underperform Votes24.88%ZIVO BioscienceOutperform Votes9960.74% Underperform Votes6439.26% Does the media favor RNAC or ZIVO? In the previous week, Cartesian Therapeutics had 12 more articles in the media than ZIVO Bioscience. MarketBeat recorded 12 mentions for Cartesian Therapeutics and 0 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 1.05 beat Cartesian Therapeutics' score of 0.50 indicating that ZIVO Bioscience is being referred to more favorably in the news media. Company Overall Sentiment Cartesian Therapeutics Neutral ZIVO Bioscience Positive Do analysts recommend RNAC or ZIVO? Cartesian Therapeutics currently has a consensus price target of $43.00, indicating a potential upside of 369.43%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cartesian Therapeutics is more favorable than ZIVO Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71ZIVO Bioscience 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger valuation and earnings, RNAC or ZIVO? ZIVO Bioscience has lower revenue, but higher earnings than Cartesian Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$34.17M6.96-$219.71M-$52.83-0.17ZIVO Bioscience$15.85K4,330.22-$7.78M-$4.93-3.65 Is RNAC or ZIVO more profitable? ZIVO Bioscience has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Company Net Margins Return on Equity Return on Assets Cartesian Therapeutics-510.72% N/A -6.03% ZIVO Bioscience N/A N/A -2,240.92% Which has more risk and volatility, RNAC or ZIVO? Cartesian Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500. SummaryCartesian Therapeutics beats ZIVO Bioscience on 11 of the 17 factors compared between the two stocks. Get ZIVO Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZIVO vs. The Competition Export to ExcelMetricZIVO BioscienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.63M$2.92B$5.34B$8.30BDividend YieldN/A1.63%5.27%4.11%P/E Ratio-3.6931.0126.9619.59Price / Sales4,330.22418.26398.82136.02Price / CashN/A168.6838.3234.64Price / Book-22.223.236.774.50Net Income-$7.78M-$72.35M$3.24B$248.60M7 Day PerformanceN/A1.84%0.27%-0.89%1 Month Performance-4.27%1.36%5.91%7.41%1 Year Performance125.56%-25.04%18.83%8.56% ZIVO Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZIVOZIVO BioscienceN/A$18.00flatN/AN/A$68.63M$15,850.00-3.6910Positive NewsRNACCartesian Therapeutics1.5222 of 5 stars$10.37+1.1%$42.50+309.8%-62.7%$269.14M$34.17M-0.2064News CoverageAnalyst RevisionTSVT2seventy bio1.4756 of 5 stars$5.00flat$4.25-15.0%N/A$266.15M$48.37M-2.69440News CoveragePositive NewsALMSAlumis2.2496 of 5 stars$5.95+5.9%$24.86+317.8%N/A$265.38MN/A0.00N/AAnalyst RevisionINZYInozyme Pharma3.0211 of 5 stars$3.99+1.0%$11.75+194.5%-13.3%$257.60MN/A-2.5650High Trading VolumeGLUEMonte Rosa Therapeutics2.0902 of 5 stars$4.11+3.3%$15.50+277.1%-4.6%$252.81M$159.49M-2.2590Positive NewsAnalyst DowngradeTERNTerns Pharmaceuticals4.0996 of 5 stars$3.15+9.4%$15.63+396.0%-49.7%$251.53MN/A-2.6740News CoveragePositive NewsGap UpPVLAPalvella Therapeutics3.8021 of 5 stars$22.56+2.3%$46.29+105.2%N/A$249.13M$42.81M-1.86N/AAnalyst RevisionLFCRLifecore Biomedical1.2417 of 5 stars$6.71-2.6%$8.00+19.2%+19.6%$248.44M$130.31M-11.98690News CoverageAnalyst ForecastAnalyst RevisionTNGXTango Therapeutics1.6895 of 5 stars$2.29+52.7%$12.33+438.6%-73.4%$248.22M$40.99M-1.9490High Trading VolumeGOSSGossamer Bio3.7981 of 5 stars$1.09+4.8%$7.75+611.0%+93.6%$247.67M$114.70M-3.41180Analyst RevisionGap Down Related Companies and Tools Related Companies RNAC Alternatives TSVT Alternatives ALMS Alternatives INZY Alternatives GLUE Alternatives TERN Alternatives PVLA Alternatives LFCR Alternatives TNGX Alternatives GOSS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZIVO) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZIVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZIVO Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
